Assignee
SUNESIS PHARMACEUTICALS INC
US·33 granted patents·28 pending applications·524 citations·filing 1998–2020
Top patents by PatentIndex Score
61 records- 0197US7314938B2Modulators of cellular adhesionSUNESIS PHARMACEUTICALS INC·Filed 2004·Granted Jan 1, 2008·86 cites·62 claims
- 0294US7115652B2Aspartyl protease inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2003·Granted Oct 3, 2006·42 cites·29 claims
- 0392US7968565B2Therapeutic combinations comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acidSUNESIS PHARMACEUTICALS INC·Filed 2005·Granted Jun 28, 2011·33 cites·1 claims
- 0492US7132568B2Aspartyl protease inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2003·Granted Nov 7, 2006·34 cites·48 claims
- 0591US6335155B1Methods for rapidly identifying small organic molecule ligands for binding to biological target moleculesSUNESIS PHARMACEUTICALS INC·Filed 1998·Granted Jan 1, 2002·92 cites·14 claims
- 0690US7989468B2Methods of using SNS-595SUNESIS PHARMACEUTICALS INC·Filed 2005·Granted Aug 2, 2011·13 cites·43 claims
- 0790US7202033B2Identification of kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2003·Granted Apr 10, 2007·70 cites·30 claims
- 0889US6878743B2Small molecule inhibitors of caspasesSUNESIS PHARMACEUTICALS INC·Filed 2002·Granted Apr 12, 2005·38 cites·43 claims
- 0986US6806279B2Small-molecule inhibitors of interleukin-2SUNESIS PHARMACEUTICALS INC·Filed 2001·Granted Oct 19, 2004·23 cites·19 claims
- 1084US10618887B2Pyrimidinyl tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2018·Granted Apr 14, 2020·3 cites·17 claims
- 1184US8822493B2SNS-595 and methods of using the sameSUNESIS PHARMACEUTICALS INC·Filed 2013·Granted Sep 2, 2014·5 cites·11 claims
- 1282US10577374B2Bruton's tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2017·Granted Mar 3, 2020·2 cites·18 claims
- 1381US6143776ATosylproline analogs as thymidylate synthase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2000·Granted Nov 7, 2000·12 cites·20 claims
- 1480US10030016B2Heterocyclic compounds useful as PDK1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2015·Granted Jul 24, 2018·2 cites·16 claims
- 1579US6784205B2Compounds that modulate the activity of PTP-1B and TC-PTPSUNESIS PHARMACEUTICALS INC·Filed 2003·Granted Aug 31, 2004·12 cites·24 claims
- 1677US6998233B2Methods for ligand discoverySUNESIS PHARMACEUTICALS INC·Filed 2002·Granted Feb 14, 2006·8 cites·12 claims
- 1777US6919178B2Extended tethering approach for rapid identification of ligandsSUNESIS PHARMACEUTICALS INC·Filed 2001·Granted Jul 19, 2005·14 cites·27 claims
- 1877US6376524B1Triphenyl compounds as interleukin-4 antagonistsSUNESIS PHARMACEUTICALS INC·Filed 2000·Granted Apr 23, 2002·14 cites·15 claims
- 1974US9980949B2SNS-595 and methods of using the sameSUNESIS PHARMACEUTICALS INC·Filed 2014·Granted May 29, 2018·1 cites·7 claims
- 2074US7601725B2Thienopyrimidines useful as Aurora kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2005·Granted Oct 13, 2009·3 cites·21 claims
- 2174US6811966B2Methods for rapidly identifying small organic molecule ligands for binding to biological target moleculesSUNESIS PHARMACEUTICALS INC·Filed 2002·Granted Nov 2, 2004·8 cites·16 claims
- 2273US9724338B2Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disordersSUNESIS PHARMACEUTICALS INC·Filed 2014·Granted Aug 8, 2017·1 cites·6 claims
- 2370US2021070752A1Heterocyclic compounds useful as pdk1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2470US2020399283A1Bruton's tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2570US2015150858A1Compounds and compositions for treatment of cancerSUNESIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2668US11174243B2Succinate forms and compositions of Bruton's tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2017·Granted Nov 16, 2021·3 cites·19 claims
- 2768US2021017155A1Pyrimidinyl tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2867US2019175589A1Pharmaceutical formulations, processes for preparation, and methods of useSUNESIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2966US2011008371A1Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disordersSUNESIS PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 3066US2018316309A1Sns-595 and methods of using the sameSUNESIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3165US7214487B2Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidatesSUNESIS PHARMACEUTICALS INC·Filed 2003·Granted May 8, 2007·5 cites·19 claims
- 3265US2020390764A1Pharmaceutical formulations, processes for preparation, and methods of useSUNESIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3364US2014378505A1Sns-595 and methods of using the sameSUNESIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3463US2019119268A1Heterocyclic compounds useful as pdk1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3562US9873693B2Methods of treatment using pyridinonyl PDK1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2014·Granted Jan 23, 2018·0 cites·15 claims
- 3662US9757363B2SNS-595 and methods of using the sameSUNESIS PHARMACEUTICALS INC·Filed 2016·Granted Sep 12, 2017·0 cites·17 claims
- 3761US9676774B2Compounds and compositions for treatment of cancerSUNESIS PHARMACEUTICALS INC·Filed 2016·Granted Jun 13, 2017·0 cites·6 claims
- 3861US9469635B2Stable SNS-595 compositions and methods of preparationSUNESIS PHARMACEUTICALS INC·Filed 2013·Granted Oct 18, 2016·0 cites·16 claims
- 3961US2010022399A1Methods for rapidly identifying small organic molecule ligands for binding to biological target moleculesSUNESIS PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4061US2014179542A1Methods for rapidly identifying small organic molecule ligands for binding to biological target moleculesSUNESIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4160US2019084978A1Stable sns-595 compositions and methods of preparationSUNESIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4260US2018370966A1Methods of treatment using pyridinonyl pdk1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4359US9969730B2Stable SNS-595 compositions and methods of preparationSUNESIS PHARMACEUTICALS INC·Filed 2016·Granted May 15, 2018·0 cites·9 claims
- 4457US2011263524A1Sns-595 and methods of using the sameSUNESIS PHARMACEUTICALS INC·Filed 2011·Application pending·0 cites
- 4556US2010179123A1Thienopyrimidines useful as aurora kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4656US2015157614A1Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acidSUNESIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4755US8802719B2Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acidSUNESIS PHARMACEUTICALS INC·Filed 2013·Granted Aug 12, 2014·0 cites·1 claims
- 4854US2007026451A1Methods for rapidly identifying small organic molecule ligands for binding to biological target moleculesSUNESIS PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 4954US2015190380A1Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disordersSUNESIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 5054US2014205679A1Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapySUNESIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →